182 related articles for article (PubMed ID: 34407143)
1. Genomics-guided identification of potential modulators of SARS-CoV-2 entry proteases, TMPRSS2 and Cathepsins B/L.
Prasad K; AlOmar SY; Almuqri EA; Rudayni HA; Kumar V
PLoS One; 2021; 16(8):e0256141. PubMed ID: 34407143
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.
Prasad K; Ahamad S; Kanipakam H; Gupta D; Kumar V
ACS Chem Neurosci; 2021 Mar; 12(5):930-944. PubMed ID: 33606519
[TBL] [Abstract][Full Text] [Related]
3. In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection.
Vivek-Ananth RP; Rana A; Rajan N; Biswal HS; Samal A
Molecules; 2020 Aug; 25(17):. PubMed ID: 32842606
[TBL] [Abstract][Full Text] [Related]
4. Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection.
Padmanabhan P; Desikan R; Dixit NM
PLoS Comput Biol; 2020 Dec; 16(12):e1008461. PubMed ID: 33290397
[TBL] [Abstract][Full Text] [Related]
5. Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators.
Gkogkou E; Barnasas G; Vougas K; Trougakos IP
Redox Biol; 2020 Sep; 36():101615. PubMed ID: 32863223
[TBL] [Abstract][Full Text] [Related]
6. Mediators of SARS-CoV-2 entry are preferentially enriched in cardiomyocytes.
Yang J; Chen T; Zhou Y
Hereditas; 2021 Jan; 158(1):4. PubMed ID: 33397514
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
8. Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression.
Gnirss K; Kühl A; Karsten C; Glowacka I; Bertram S; Kaup F; Hofmann H; Pöhlmann S
Virology; 2012 Mar; 424(1):3-10. PubMed ID: 22222211
[TBL] [Abstract][Full Text] [Related]
9. Modelling how increased Cathepsin B/L and decreased TMPRSS2 usage for cell entry by the SARS-CoV-2 Omicron variant may affect the efficacy and synergy of TMPRSS2 and Cathepsin B/L inhibitors.
Padmanabhan P; Dixit NM
J Theor Biol; 2023 Sep; 572():111568. PubMed ID: 37393986
[TBL] [Abstract][Full Text] [Related]
10. Multiple sites on SARS-CoV-2 spike protein are susceptible to proteolysis by cathepsins B, K, L, S, and V.
Bollavaram K; Leeman TH; Lee MW; Kulkarni A; Upshaw SG; Yang J; Song H; Platt MO
Protein Sci; 2021 Jun; 30(6):1131-1143. PubMed ID: 33786919
[TBL] [Abstract][Full Text] [Related]
11. Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2.
Li Y; Wang K; Sun H; Wu S; Wang H; Shi Y; Li X; Yan H; Yang G; Wu M; Li Y; Ding X; Si S; Jiang J; Du Y; Li Y; Hong B
Antiviral Res; 2023 Jun; 214():105606. PubMed ID: 37076089
[TBL] [Abstract][Full Text] [Related]
12. TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells.
Koch J; Uckeley ZM; Doldan P; Stanifer M; Boulant S; Lozach PY
EMBO J; 2021 Aug; 40(16):e107821. PubMed ID: 34159616
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models.
Mykytyn AZ; Breugem TI; Geurts MH; Beumer J; Schipper D; van Acker R; van den Doel PB; van Royen ME; Zhang J; Clevers H; Haagmans BL; Lamers MM
J Virol; 2023 Aug; 97(8):e0085123. PubMed ID: 37555660
[TBL] [Abstract][Full Text] [Related]
14. Pan‑cancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARS‑CoV‑2 infection leading to COVID-19.
Katopodis P; Anikin V; Randeva HS; Spandidos DA; Chatha K; Kyrou I; Karteris E
Int J Oncol; 2020 Aug; 57(2):533-539. PubMed ID: 32468052
[TBL] [Abstract][Full Text] [Related]
15. Genomic, epigenomic, and immune subtype analysis of CTSL/B and SARS-CoV-2 receptor ACE2 in pan-cancer.
Li H; Xie L; Chen L; Zhang L; Han Y; Yan Z; Guo X
Aging (Albany NY); 2020 Nov; 12(22):22370-22389. PubMed ID: 33231569
[TBL] [Abstract][Full Text] [Related]
16. Protease inhibitors targeting coronavirus and filovirus entry.
Zhou Y; Vedantham P; Lu K; Agudelo J; Carrion R; Nunneley JW; Barnard D; Pöhlmann S; McKerrow JH; Renslo AR; Simmons G
Antiviral Res; 2015 Apr; 116():76-84. PubMed ID: 25666761
[TBL] [Abstract][Full Text] [Related]
17. Middle East Respiratory Syndrome Coronavirus Spike Protein Is Not Activated Directly by Cellular Furin during Viral Entry into Target Cells.
Matsuyama S; Shirato K; Kawase M; Terada Y; Kawachi K; Fukushi S; Kamitani W
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021905
[TBL] [Abstract][Full Text] [Related]
18. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
19. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.
Kumar V; Dhanjal JK; Bhargava P; Kaul A; Wang J; Zhang H; Kaul SC; Wadhwa R; Sundar D
J Biomol Struct Dyn; 2022 Jan; 40(1):1-13. PubMed ID: 32469279
[TBL] [Abstract][Full Text] [Related]
20. Clinical Isolates of Human Coronavirus 229E Bypass the Endosome for Cell Entry.
Shirato K; Kanou K; Kawase M; Matsuyama S
J Virol; 2017 Jan; 91(1):. PubMed ID: 27733646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
